Literature DB >> 27049304

A novel kinase mutation in VEGFR-1 predisposes its αC-helix/activation loop towards allosteric activation: Atomic insights from protein simulation.

Taseem A Mokhdomi1, Shoiab Bukhari1,2, Naveed Anjum Chikan1, Asif Amin1, Asrar H Wafai1, Sajad H Wani1, Nisar A Chowdri3, Raies A Qadri1.   

Abstract

Vascular endothelial growth factor receptor 1 (VEGFR-1) has been implicated in diverse pathologies, including cancers. Although VEGFR-1 is considered as functionally impaired kinase, its decoy characteristics make it an important regulator of VEGFR-mediated signaling, particularly in tumor angiogenesis. VEGFR-1 conveys signaling via its tyrosine kinase (TK) domain whose activation is regulated by phosphorylation of specific tyrosine residues. Thus dysregulation of VEGFR-1 signaling, as reported in most of the cancers, might be a consequence of altered phosphorylation that could be attributed to genotypic variations in its TK domain. Considering the importance of TK domain of VEGFR-1, we carried out its mutational screening in 84 clinically validated and histopathologically confirmed colorectal cancer patients. By means of direct DNA sequencing and SNP analyses, eight novel variations, including one synonymous, two deletion, one missense and four intronic variations, were reported in the TK domain of VEGFR-1. rs730882263:C>G variation specifically reported in colon cancer, representing a single-atomic change (Sulfur to Oxygen) in the predicted (p.Cys1110Ser) protein, was observed as potentially deleterious variation as assessed by multiple single-nucleotide polymorphism prediction servers. Molecular dynamics simulations of VEGFR-1 Wt and (p.Cys1110Ser) variant models revealed major conformational changes in variant protein presumptuously generating an open conformation thereby exposing the activation domain and consequently increasing the probability of phosphorylation events: a condition frequently reported in cancers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27049304      PMCID: PMC4989210          DOI: 10.1038/ejhg.2016.26

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  31 in total

1.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

Authors:  P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  MutationTaster2: mutation prediction for the deep-sequencing age.

Authors:  Jana Marie Schwarz; David N Cooper; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2014-04       Impact factor: 28.547

3.  A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1.

Authors:  Rosana D Meyer; Moosa Mohammadi; Nader Rahimi
Journal:  J Biol Chem       Date:  2005-11-14       Impact factor: 5.157

4.  A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration.

Authors:  H Gille; J Kowalski; L Yu; H Chen; M T Pisabarro; T Davis-Smyth; N Ferrara
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

Review 5.  Pharmacogenetics, pharmacogenomics, and individualized medicine.

Authors:  Qiang Ma; Anthony Y H Lu
Journal:  Pharmacol Rev       Date:  2011-03-24       Impact factor: 25.468

6.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

Review 7.  Positive and negative modulation of angiogenesis by VEGFR1 ligands.

Authors:  Yihai Cao
Journal:  Sci Signal       Date:  2009-02-24       Impact factor: 8.192

8.  Predicting the functional effect of amino acid substitutions and indels.

Authors:  Yongwook Choi; Gregory E Sims; Sean Murphy; Jason R Miller; Agnes P Chan
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

9.  Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.

Authors:  K Yoshimura; T Minami; M Nozawa; H Uemura
Journal:  Br J Cancer       Date:  2013-03-07       Impact factor: 7.640

10.  Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-1 overexpression in peripheral blood.

Authors:  Y Kosaka; K Mimori; T Fukagawa; K Ishikawa; T Etoh; H Katai; T Sano; M Watanabe; M Sasako; M Mori
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640

View more
  2 in total

1.  Aqueous solution interactions with sex hormone-binding globulin and estradiol: a theoretical investigation.

Authors:  A J da Silva; E S Dos Santos
Journal:  J Biol Phys       Date:  2018-07-05       Impact factor: 1.365

2.  Structural insight into mutations at 155 position of valosin containing protein (VCP) linked to inclusion body myopathy with Paget disease of bone and frontotemporal Dementia.

Authors:  Rui Wu; Zhijie Wei; Li Zhang
Journal:  Saudi J Biol Sci       Date:  2021-02-19       Impact factor: 4.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.